-
Article
Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most important cause of chronic liver disease in the western world. Steatosis can be accompanied by inflammation and cell damage (non-alcoholic steatohepatitis,...
-
Article
Open AccessHealth-related costs in a sample of premenopausal non-diabetic overweight or obese females in Antwerp region: a cost-of-illness analysis
People with overweight or obesity are at increased risk for disease later in life which cause important health costs.
-
Article
Open AccessLEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk. We used the baseline data of liraglutide effect and action in diabet...
-
Article
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial
The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term s...
-
Article
Incidence and predisposing factors for the development of disturbed glucose metabolism and diabetes mellitus after intensive care admission: the DIAFIC study
-
Article
Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance
To examine the specific distribution of liver fat content, visceral and subcutaneous adiposity in normal glucose tolerance (NGT/NGT), isolated impaired fasting glucose (iIFG), isolated impaired glucose toleran...
-
Article
Open AccessTolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
Liraglutide 3.0 mg, with diet and exercise, produced substantial weight loss over 1 year that was sustained over 2 years in obese non-diabetic adults. Nausea was the most frequent side effect.
-
Article
Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
Correction to: International Journal of Obesity 36: 843–854; doi:10.1038/ijo.2011.158 Since publication of this article the authors have noticed the following errors. The original article has not been amended ...
-
Article
Erratum to: Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes
-
Article
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes
The optimal HbA1c concentration for prevention of macrovascular complications and deaths in obese cardiovascular high-risk patients with type 2 diabetes remains to be established and was therefore studied in this...
-
Article
Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
Correction to: International Journal of Obesity advance online publication 16 August 2011; doi: 10.1038/ijo.2011.158 Since the publication of this article the authors have noticed an error in one of the figure...
-
Article
Open AccessSafety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary out...
-
Article
Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension
We previously demonstrated in an animal model that steatosis, in the absence of fibrosis, induces a significant rise in portal pressure, indicating substantial changes in liver hemodynamics. As assessment of p...
-
Article
Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients
To study the relationship between elevated liver tests and high sensitive C-reactive protein (hs-CRP), as potential markers of liver inflammation and non-alcoholic steatohepatitis (NASH), with anthropometric a...
-
Article
Cost Effectiveness of Atorvastatin in Patients with Type 2 Diabetes Mellitus
Background and Objective: Patients with type 2 diabetes mellitus have a high risk of develo** cardiovascular (CV) disease. The clinical benefit of use of statins in patients with type 2 diabete...
-
Article
Is sleep-disordered breathing an additional risk factor for the metabolic syndrome in obese children and adolescents?
Sleep-disordered breathing is highly prevalent in childhood obesity. Two recent cross-sectional studies have demonstrated an independent association between the severity of sleep-disordered breathing and the m...
-
Article
Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives
Insulin resistance has been proposed as a risk factor for type 1 diabetes. We investigated whether adiponectin, an insulin sensitiser, can serve as an additional predictive marker for type 1 diabetes in first-...
-
Article
Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes
The incidence of type 1 diabetes varies according to age, sex and season of diagnosis. We investigated whether these and other clinical, biological and anthropometric parameters were correlated with residual b...
-
Article
Screening for melanocortin-4 receptor mutations in a cohort of Belgian morbidly obese adults and children
To investigate whether pathogenic melanocortin-4 receptor (MC4R) mutations are a common cause of obesity in Belgium.
-
Article
Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring
